 Finch Therapeutics Group Inc NASDAQ: FNCH announced that Takeda Pharmaceutical Company Limited NYSE: TAK has elected to take the lead on the development of FIN-524, now known as TAK-524, in ulcerative colitis. When Takeda teamed up with Finch Therapeutics in 2017 on inflammatory bowel disease IBD, it planned to pick up programs after theyd finished Phase 2 trials. 